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Background: Diminished brain levels of two neurohormones, 5-hydroxytryptamine (5-HT; serotonin) and 1,25-
dihydroxyvitamin D3 (1,25D; active vitamin D metabolite), are proposed to play a role in the atypical social behaviors
associated with psychological conditions including autism spectrum disorders and depression. We reported previously
that 1,25D induces expression of tryptophan hydroxylase-2 (TPH2), the initial and rate-limiting enzyme in the biosynthetic
pathway to 5-HT, in cultured rat serotonergic neuronal cells. However, other enzymes and transporters in the pathway of
tryptophan metabolism had yet to be examined with respect to the actions of vitamin D. Herein, we probed the
response of neuronal cells to 1,25D by quantifying mRNA expression of serotonin synthesis isozymes, TPH1 and TPH2, as
well as expression of the serotonin reuptake transporter (SERT), and the enzyme responsible for serotonin catabolism,
monoamine oxidase-A (MAO-A). We also assessed the direct production of serotonin in cell culture in response to 1,25D.
Results: Employing quantitative real-time PCR, we demonstrate that TPH-1/-2 mRNAs are 28- to 33-fold induced by
10 nM 1,25D treatment of cultured rat serotonergic neuronal cells (RN46A-B14), and the enhancement of TPH2 mRNA
by 1,25D is dependent on the degree of neuron-like character of the cells. In contrast, examination of SERT, the gene
product of which is a target for the SSRI-class of antidepressants, and MAO-A, which encodes the predominant catabolic
enzyme in the serotonin pathway, reveals that their mRNAs are 51–59% repressed by 10 nM 1,25D treatment of RN46A-
B14 cells. Finally, serotonin concentrations are significantly enhanced (2.9-fold) by 10 nM 1,25D in this system.
Conclusions: These results are consistent with the concept that vitamin D maintains extracellular fluid serotonin
concentrations in the brain, thereby offering an explanation for how vitamin D could influence the trajectory and
development of neuropsychiatric disorders. Given the profile of gene regulation in cultured RN46A-B14 serotonergic
neurons, we conclude that 1,25D acts not only to induce serotonin synthesis, but also functions at an indirect, molecular-
genomic stage to mimic SSRIs and MAO inhibitors, likely elevating serotonin in the CNS. These data suggest that optimal
vitamin D status may contribute to improving behavioral pathophysiologies resulting from dysregulation of serotonergic
neurotransmission.
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Serotonin, a neurotransmitter derived from the nutri-
tionally essential amino acid tryptophan, executes critical
functions in the brain such as control of appetite, energy
expenditure, sleep, temperature, mood, and social cogni-
tion [1]. Serotonergic neurons innervate vast areas of the
brain, with projections arising from cell bodies in the dor-
sal and median raphe and neighboring nuclei of the lower
brain stem. These projections radiate to the hippocampus,
amygdala, hypothalamus, nucleus accumbens, and lateral
prefrontal cortex, as well as to a widespread array of cor-
tical areas, wherein serotonin modulates a broad range of
behavioral actions via metabotropic G protein-coupled
and ionotropic, ligand-gated ion channel receptors [2].
In what constitutes the first step of serotonin produc-
tion, tryptophan in the CNS is hydroxylated to 5-
hydroxytryptophan by the enzyme tryptophan hydroxy-
lase type 2 (TPH2), the rate-limiting step in brain sero-
tonin synthesis. This is followed by subsequent
decarboxylation of 5-hydroxytryptophan, catalyzed by
aromatic amino acid decarboxylase, to serotonin (5-hy-
droxytryptamine; 5-HT). Serotonin is then packaged by
vesicularization through the action of monoamine trans-
porter isoform 2 in raphe neurons. After the release of
5-HT-containing vesicles from axon terminals, and sub-
sequent reuptake of serotonin from the synapse via a
serotonin reuptake transporter (SERT), degradation of
serotonin is catalyzed by monoamine oxidase-A
(MAO-A) and aldehyde dehydrogenase to the predomin-
ant serotonin metabolite, 5-hydroxyindoleacetic acid [2].
Therefore, three important enzymes/transport proteins
that determine serotonin concentration and dynamics in
the CNS are TPH2, SERT, and MAO-A. It is generally
accepted that the amount and activity of these three pro-
teins governs serotonin levels in the CNS [3].
In a recent publication [4], we proposed that serotonin
concentrations are controlled in part by 1,25-dihydroxy-
vitamin D3 (1,25D), the active, hormonal metabolite of
vitamin D. Specifically, we demonstrated that 1,25D dra-
matically induces TPH2 gene expression in differentiated
serotonergic rat raphe RN46A-B14 cells [4], a finding
that is reinforced by in vivo experiments conducted by
Jiang et al. [5] revealing a significant induction of TPH2
mRNA in the prefrontal cortex of rats after chronic
1,25D administration. Central among the plethora of
serotonin bioeffects are those that influence executive
function, sensory gating, and prosocial behavior; import-
antly, serotonin levels are often suboptimal in disorders
of these actions. Patrick and Ames [6] have reviewed the
observed association between aberrant serotonin con-
centrations, both during development and in the adult,
in a broad range of behavioral illnesses including ADHD,
autism, bipolar disorder, depression, and schizophrenia,
as well as anti-social, obsessive-compulsive, and suicidalbehaviors. They hypothesized that an association be-
tween vitamin D insufficiency and low central serotonin
concentrations represents a common denominator in a
myriad of neuropsychiatric disorders. While it is con-
ceivable that the ability of the vitamin D hormone,
1,25D, to upregulate TPH2 expression is a key factor in
maintaining serotonin output by serotonergic neurons,
other avenues of serotonin metabolism have yet to be in-
vestigated with respect to the effects of vitamin D. In
the present communication, we examined the influence
of a range of 1,25D concentrations on the expression of
SERT, MAO-A/B, and TPH-1/2 to elucidate the mechan-
ism of action underlying the regulation of serotonin re-
uptake, degradation, and synthesis by vitamin D in
serotonergic neurons.
Results
To determine if vitamin D affects the major route of
serotonin reuptake and degradation, the influence of
1,25D on the expression of SERT and MAO-A was
assessed by quantitative real-time PCR in differentiated
serotonergic rat raphe RN46A-B14 cells. Cells in culture
were challenged with 1, 10, and 100 nM 1,25D, and
mRNA was isolated, reverse transcribed to cDNA and
probed for SERT and MAO-A expression. Figure 1a illus-
trates that SERT is unaffected by 1 and 100 nM
1,25D-treatment, but a concentration of 10 nM 1,25D
significantly (p = 0.0001) represses SERT mRNA expres-
sion by 59%. Thus, the response of SERT to 1,25D is
biphasic, reminiscent of the U-shaped curves generated
when plotting circulating 25-hydroxyvitamin D levels
versus disease and death in humans [7]. Strikingly,
MAO-A displays an identical regulatory pattern of
expression when challenged with a range of 1,25D con-
centrations in differentiated serotonergic rat raphe
RN46A-B14 cells (Fig. 1b). MAO-A is similarly un-
affected by 1 and 100 nM 1,25D-treatment, but a con-
centration of 10 nM 1,25D significantly (p = 0.015)
represses MAO-A mRNA expression by 51%. Therefore,
two neurally expressed genes exhibit a similar profile of
regulation by 1,25D, and the data suggest that certain
levels of the vitamin D hormone appear to be capable of
suppressing serotonin reuptake and catabolism.
As a negative-control neural gene, MAO-B was evalu-
ated for modulation of expression by 1,25D in
RN46A-B14 cells (Fig. 1c). Interestingly, MAO-B was
not significantly repressed by 1,25D at any of the tested
dosages, indicating that the influence of 1,25D on SERT
and MAO-A expression may be selective for biologically
relevant serotonin metabolism genes. Furthermore, as a
positive control to confirm endogenous expression of a
sufficient copy number of biologically functional nuclear
vitamin D receptors (VDRs) to mediate transcriptional
regulation by 1,25D in RN46A-B14 cells, we examined
ba
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Fig. 1 Effect of 1,25D on selected serotonin degrading pathway and control mRNAs in a serotonergic neuronal cell line. P values listed at the top
of bars represent statistical significance for comparison between 1,25D treatment and ethanol vehicle control group in each and all cases.
Statistical analyses were performed using ANOVA with a post hoc adjustment of P values via the Dunnett test that compares every mean to a
control mean and takes into account the scatter of all the groups. a Expression of SERT in serotonergic rat raphe RN46A-B14 cells treated with
1,25D. Each mRNA value is the average of nine biological replicates ± std. dev. b Expression of MAO-A in serotonergic rat raphe RN46A-B14 cells
treated with 1,25D. Each mRNA value is the average of nine biological replicates ± std. dev. c Expression of MAO-B in serotonergic rat raphe
RN46A-B14 cells treated with 1,25D. Each mRNA value is the average of 18 biological replicates ± std. dev. d Expression of Cyp24a1 in
serotonergic rat raphe RN46A-B14 cells treated with 1,25D. Each mRNA value is the average of nine biological replicates ± std. dev
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min D hormone. As depicted in Fig. 1d, Cyp24a1 expres-
sion is dramatically (38- to 116-fold) augmented by
exposure of the cells to 1–100 nM 1,25D, with the pertin-
ent observation that this gene displayed the traditional
dose-response curve for induction. Cyp24a1 serves not
only as a control for positive modulation of gene expres-
sion via VDR in RN46A-B14 cells, but because the RNA
probed was isolated from the same treated cells for SERT
and MAO-A mRNA assessment, any systematic error in
the technology can be eliminated from consideration as
an explanation for the unique dose-response results for
serotonin catabolic gene expression.
Next, we determined if 1,25D exerted actions on the
expression of SERT, MAO-A, MAO-B, and CYP24A1 in
the human glioblastoma cell line, U-87 MG (U87), which
does not exhibit serotonergic neuronal characteristics. In
contrast to the results in RN46A-B14 cells, the data for
U87 cells reveal that 1,25D does not significantly alter
the expression of either SERT or MAO-A in glioblastoma
cells (Fig. 2a, b). This observation suggests that the
repressive modulation of these two serotonin-degradativereactions by 1,25D may be specific for serotonergic neu-
rons. Further, as depicted in Fig. 2c, unlike in RN46A-B14
cells, 1,25D significantly represses (25%, p = 0.005)
MAO-B mRNA levels in U87 cells, pointing to a potential
selectivity of 1,25D action on the MAO-B isozyme in
regions of the CNS separate from serotonergic neuro-
transmission. Interestingly, the same biphasic pattern of
U-shaped dose-responsiveness to 1,25D obtained for SERT
and MAO-A repression in RN46A-B14 cells occurs for
MAO-B in U87 cells in terms of the optimal repressive
dose of 1,25D being 10 nM. That this finding is valid is
supported by the classic dose-response relationship occur-
ring for 1,25D induction of CYP24A1 in U87 cells (Fig. 2d),
which serves as a positive control.
In order to investigate the influence of serotonergic
neuronal cell state on the control of serotonin synthesis
by 1,25D, we next studied RN46A-B14 cells cultured in
three different media formulations designed to generate
varying degrees of neuronal morphology. The three
media, designated media 1, 2, and 3, are described in de-
tail in the “Methods” section. Figure 3a pictorially repre-
sents RN46A-B14 cells grown in media 1, illustrating
a b
c d
Fig. 2 Effect of 1,25D on serotonin degrading pathway and control mRNAs in U87 glioblastoma cells. P values listed at the top of bars represent
statistical significance for comparison between 1,25D-treatment and ethanol vehicle control group in each and all cases. Statistical analyses were
performed using ANOVA with a post hoc adjustment of P values via the Dunnett test that compares every mean to a control mean and takes
into account the scatter of all the groups. a Expression of SERT in U87 human glioblastoma cells treated with 1,25D. Each mRNA value is the
average of seven biological replicates ± std. dev. b Expression of MAO-A in U87 human glioblastoma cells treated with 1,25D. Each mRNA value is
the average of 11 biological replicates ± std. dev. c Expression of MAO-B in U87 glioblastoma cells treated with 1,25D. Each mRNA value is the
average of 27 biological replicates ± std. dev. d Expression of CYP24A1 in U87 glioblastoma cells treated with 1,25D. Each mRNA value represents
the average of seven biological replicates ± std. dev
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nections; cells maintained in media 1 displayed the most
neuronal-like morphology and exhibited the slowest
growth rate among the tested media. Figure 3b shows
RN46A-B14 cells grown in media 2, with the cells
retaining generally neuronal morphology, but acquiring
some fibroblast-like character with increased growth rate
and confluency. RN46A-B14 cells maintained in media 3
(Fig. 3c) displayed mostly fibroblast morphology during
proliferation, with the fastest growth rate, likely induced
by components of fetal bovine serum (FBS) and add-
itional glucose, both present in the media. Therefore,
media 1 elicited the most neuron-like character in
RN46A-B14 cells, and the cells assumed a more
fibroblast-like morphology and proliferated more rapidly
as the media progressed from 1 to 3. Figure 3d depicts
the results of TPH2 mRNA induction by treatment with
10 nM 1,25D for 24 h of RN46A-B14 cells maintained in
media 1–3. TPH2 was significantly (32-fold) induced by
1,25D only in media 1, revealing that 1,25D regulation of
tryptophan metabolizing gene products occurs in cells
most resembling serotonergic neurons.Next, the concentration-dependence of 1,25D-regula-
tion of both TPH1 and TPH2 mRNAs was evaluated in
RN46A-B14 cells maintained in media 1. As illustrated
in Fig. 4a, the profile of TPH1 mRNA response to 1,25D
as a function of concentration of the vitamin D hormone
is analogous to the results obtained for SERT and
MAO-A but inverted, in that treatment of the cells with
1 or 100 nM 1,25D is without significant effect whereas
exposure of the cells to 10 nM 1,25D induces TPH1
28-fold. Again, this biphasic induction over a range of
hormone concentrations is not the consequence of ex-
perimental error because when assayed in RNA from the
same biological replicate cells, Cyp24a1 mRNA exhibits
the traditional dose-response curve for induction follow-
ing treatment of the cells with 1,25D (Fig. 4c). This
non-traditional inverted U-shaped dose response is ad-
dressed in the “Discussion” section, but at present the
authors postulate that specific, CNS-expressed genes
may be modulated in their expression differently than
are typical vitamin D target genes in peripheral tissues
such as bone, intestine, and kidney. Consistent with this
interpretation is the 1,25D concentration-dependence of
a b c
d
Fig. 3 Morphology of serotonergic rat raphe RN46A-B14 cells grown in a media 1, b media 2, and c media 3, see the “Methods” section for
descriptions of the media formulations. d RN46A-B14 cells grown in media 1–3 and treated with 10 nM 1,25D for 24 h, followed by TPH2 mRNA
quantification, expressed as fold relative to EtOH vehicle control (not shown)
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TPH2 is documented to be the isoform that is respon-
sible for catalyzing brain serotonin synthesis in the adult
[8]. In non-neuronal serotonergic cells, TPH1 mRNA is
the primary isoform expressed, whereas serotonergic
neurons express TPH2 mRNA predominantly [9]. As
depicted in Fig. 4b, the profile of TPH2 mRNA response
to 1,25D as a function of concentration of the vitamin D
hormone mimics the pattern of regulation of TPH1, in
that treatment of the cells with 1 or 100 nM 1,25D pro-
duces no significant effect on TPH2 mRNA, whereas ex-
posure of the cells to 10 nM 1,25D induces TPH2
33-fold (p < 0.0001). What could be important withba
Fig. 4 Effect of 1,25D on TPH1, TPH2 and Cyp24a1 mRNAs in a serotonergic
statistical significance for comparison between 1,25D-treatment and ethano
performed using ANOVA with a post hoc adjustment of P values via the D
into account the scatter of all the groups. a Expression of TPH1 in serotone
values for 1 and 100 nM 1,25D are too small to be perceived in the figure
value is the average of nine biological replicates ± std. dev. b Expression of
The exact fold-effect values for 1 and 100 nM 1,25D are too small to be pe
respectively. Each mRNA value is the average of 30 biological replicates ± s
cells treated with 1,25D. Each mRNA value is the average of 20 biological rrespect to serotonin dynamics is that the inverted
U-shaped curve for TPH2 induction by 1,25D as a func-
tion of concentration of hormone (Fig. 4b) is comple-
mentary to the U-shaped curves for SERT (Fig. 1a) and
MAO-A (Fig. 1b) mRNA repression in response to in-
creasing 1,25D concentration.
In a final set of in vitro experiments, RN46A-B14 cells
were exposed to 1, 10, or 100 nM 1,25D for 72 h and
serotonin concentrations were quantified by 5-HT
ELISA of the cell culture medium. Interestingly, 1 nM
1,25D exerted a slight (15%), non-significant suppression
of serotonin compared to ethanol vehicle control, which
contrasted to the 2.9-fold increase (p < 0.05) in serotoninc
neuronal cell line. P values listed at the top of bars represent
l vehicle control group in each and all cases. Statistical analyses were
unnett test that compares every mean to a control mean and takes
rgic rat raphe RN46A-B14 cells treated with 1,25D. The exact fold-effect
as scaled; they are 0.41 ± 0.22 and 0.73 ± 0.17, respectively. Each mRNA
TPH2 in serotonergic rat raphe RN46A-B14 cells treated with 1,25D.
rceived in the figure as scaled; they are 0.36 ± 0.23 and 0.65 ± 0.31,
td. dev. c Expression of Cyp24a1 in serotonergic rat raphe RN46A-B14
eplicates ± std. dev
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ing that this assay is cumulative, Fig. 5a also illustrates
that 100 nM 1,25D treatment of RN46A-B14 cells pro-
duced a diminished induction of serotonin to 2.0-fold,
generating a biphasic dose-response curve for total sero-
tonin that reflects the biphasic dose-response curves for
the induction of TPH2 as well as for the repression of
SERT and MAO-A. Taken together, this stimulatory ef-
fect of 10 nM 1,25D on serotonin synthesis, coupled
with suppressive actions on serotonin reuptake and
metabolic elimination, resulting in almost a tripling of
total free serotonin, vividly integrates what a significant
effect an optimal concentration of 1,25D (10 nM) exerts
to bolster extracellular serotonin. Figure 5b displays the
time-course of serotonin enhancement by 10 nM 1,25D
in RN46A-B14 cell culture. Augmented serotonin is ap-
parent at 24 h (1.7-fold; p < 0.05), levels off at 48 hFig. 5 Effect of 1,25D on total 5-HT levels in rat serotonergic neuron cell cu
serotonergic rat raphe RN46A-B14 cells treated with the indicated concent
was removed from each plate after 72 h of treatment and 5-HT quantitated
of three biological replicates (n = 3) ± SD, with duplicate or triplicate sampl
out in RN46A-B14 cells treated with the optimal concentration of 1,25D (10
of medium from each plate and serotonin assayed by 5-HT ELISA. Values a
or triplicate sample groups averaged in each case(1.6-fold; p < 0.05), and reaches 2.0-fold (p < 0.05) by
72 h of exposure to 1,25D versus control ethanol vehicle.
Such a time-course is consistent with induction/repres-
sion but does not distinguish between primary and sec-
ondary mechanisms.
Discussion
Although recent research has highlighted the possible
significance of the relationship between vitamin D and
the tryptophan-derived neurotransmitter, serotonin [4],
previous studies focused solely on serotonin synthesis.
In the present communication, we have investigated, for
the first time, the effects of 1,25D on the regulation of
serotonin reuptake via a serotonin reuptake transporter
and on the first step of serotonin degradation by
monoamine oxidase-A in serotoninergic neuronal cell
lines. SERT (SLC6A4, 5HTT), the 5-HT transporter,lture medium. a A dose-response experiment was performed in
rations of 1,25D or ethanol (EtOH) vehicle. A 200 μL sample of medium
by ELISA as detailed in the “Methods” section. Values are the average
es averaged in each group. b A time-course experiment was carried
nM) for 0, 24, 48, and 72 h followed by removal of a 200 μL sample
re the average of three biological replicates (n = 3) ± SD, with duplicate
Sabir et al. Genes & Nutrition  (2018) 13:19 Page 7 of 11plays a crucial role in the control of serotonergic neuro-
transmission by determining the magnitude and dur-
ation of the 5-HT synaptic signal and has been an
attractive target in rational neuropsychiatric drug design
[10]. Fluoxetine (Prozac), citalopram (Celexa), paroxetine
(Paxil), and sertraline (Zoloft) represent selective inhibi-
tors of SERT. In the presence of these selective serotonin
reuptake inhibitors (SSRIs), 5-HT remains in the extra-
cellular space for an extended duration, allowing pro-
longed 5-HT receptor activation in the postsynaptic
neuron. Thus, monoamine transporters such as SERT
constitute the primary mechanism for terminating
neurotransmission through removal of the released
transmitter from the synaptic cleft. These transporters,
including SERT, function as oligomeric complexes in the
cell membrane, and are regulated primarily through
phosphorylation, protein-protein interactions, and traf-
ficking events [11]. Limited data are available on the
control of SERT at the transcriptional level, although the
genes encoding mammalian forms have been cloned
[12]. The 5-prime flanking region of the SERT (5HTT)
human gene contains a cyclic AMP-responsive element
(CRE) at − 99 bp plus binding sites for AP-1, AP-2, and
SP1, all just upstream of a TATA-like motif. Sequences
within − 1.4 kb of the transcription start site confer
cell-specific expression, and the basal promoter responds
to induction by cAMP [12]. A functional polymorphism
(5HTT-LPR) has been identified in the human 5HTT
promoter [13], and evidence has accumulated for an as-
sociation between alleles of this variation and anxiety
traits, affective disorders, as well as autism. Notably,
three ChIP-seq databases generated in human immune
cells for 1,25D-dependent occupation of vitamin
D-responsive elements (VDREs) by VDR yield appar-
ently functional sites at − 64.5 and + 118 kb in relation
to the transcription start site of the SERT gene [14–16].
Thus, 1,25D could potentially modulate human SERT
expression in a primary fashion via remote VDREs.
Examining the influence of 1,25D on SERT mRNA ex-
pression in rat raphe RN46A-B14 cells, we observed a
repression of SERT mRNA by 59% when the cells were
treated with 10 nM 1,25D (Fig. 1a). This repression was
selective for serotonergic neuronal cells in that it was
not found in U87 human glioblastoma cells (Fig. 2a).
The initial conclusion is that 1,25D, analogous to SSRIs,
suppresses serotonin reuptake, possibly potentiating se-
rotonergic neurotransmission. However, this conclusion
must be reached with caution, because neither 1 nor
100 nM 1,25D treatment of RN46A-B14 cells signifi-
cantly represses SERT mRNA expression (Fig. 1a), gener-
ating an unusual, biphasic dose-response curve.
Nevertheless, this dose response is reminiscent of the
U-shaped curves generated when plotting circulating
25-hydroxyvitamin D levels versus disease in humans,most recently reported in a study of autism risk in
3-year-old Chinese children as a function of circulating
25-hydroxyvitamin D levels at birth [17]. In other words,
there appears to exist an optimal level of circulating vita-
min D for health, and this may correspond empirically
to 10 nM 1,25D in the case of RN46A-B14 cell
treatment.
However, the cellular and molecular mechanism that
accounts for the observed effects of various concentra-
tions of 1,25D in RN46A-B14 cell treatment experiments
requires careful consideration. The authors favor the
concept that limited, but more physiologically relevant,
concentrations of 1,25D signal biologic actions such as
cell proliferation, whereas higher levels of the hormone
cause the opposing responses, namely inhibition of cell
growth and apoptosis. We first identified this
phenomenon when studying osteosarcoma cells in cul-
ture, observing that low concentrations of 1,25D stimu-
lated cell growth, whereas higher levels drastically
curbed proliferation [18]. Therefore, we propose that the
data in Fig. 1a can be explained if one assumes that the
minimum effective concentration to stimulate prolifera-
tion (and other effects such as altered transcription fac-
tor profile and epigenetic modifications) in RN46A-B14
cells is 10 nM 1,25D, conditioning the neuronal cells to
exhibit a repression of SERT expression, then the lack of
response to treatment with 1 nM is appropriate. If one
then assumes that 100 nM 1,25D, analogous to the ac-
tion of this level in many cell types, promulgates an in-
hibition of cell proliferation with attending alteration of
transcription factor profile and epigenetic modifications,
then the lack of responsiveness of SERT expression to
this higher dose of 1,25D of these growth-inhibited
RN46A-B14 cells is also readily explainable. Neverthe-
less, the observations, in vitro, that higher concentra-
tions of 1,25D are less effective than 10 nM hormone
must be viewed with some skepticism and it will ultim-
ately need to be determined if data from cell lines can
be directly equated to the U-shaped dose-response
curves, in vivo, because cell growth aspects and cell cul-
ture conditions (i.e., interaction with other media com-
ponents) could be responsible for the results with high
1,25D concentrations. However, very recent data ob-
tained in autistic children suggest that maintaining cir-
culating 25-hydroxyvitamin D levels in an optimal range
elicits maximal therapeutic efficacy in vitamin
D-responsive children [19]. Regardless of the mechanis-
tic nuances, we provide herein more support for the
vitamin D-serotonin hypothesis in the pathophysiology
of neuropsychiatric disease that has been professed by
Patrick and Ames [1, 6]. Consistent with the relevance
of SERT modulation by 1,25D is a report [20] of in-
creased concentrations of SERT protein (monitored by
positron emission tomography (PET) brain scans) in
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levels in SAD patients were 5% higher in winter, when
vitamin D generated by sunlight is deficient, than in
summer when sunlight is at a maximum; control
subjects without SAD manifest no change in SERT levels
with season. It is accepted that sunlight is mood-
elevating, and the 1,25D effect to repress SERT reported
herein may represent a facet of this benefit.
When examining MAO-A modulation by 1,25D in rat
raphe RN46A-B14 cells, we observed a repression of
MAO-A mRNA by 51% when the cells were treated with
10 nM 1,25D (Fig. 1b). The 1,25D dose-response profile
was equivalent for MAO-A and SERT repression, and
the effect on MAO-A was also selective for serotonergic
neuronal cells as it was not found in U87 human glio-
blastoma cells (Fig. 2b). Thus, the same arguments can
be applied in discussing the control of MAO-A by 1,25D
that were elaborated above for SERT repression. How-
ever, there exists a caveat to the observed repression of
MAO-A by 1,25D in cultured rat serotonergic cells, in
that Jiang et al. [5] demonstrated a significant induction
of MAO-A mRNA in the prefrontal cortex of rats after
chronic 1,25D administration. This conflict between the
in vitro and in vivo results with respect to MAO-A
could be because Jiang et al. [5] analyzed the entire pre-
frontal cortex, whereas the cell culture data are selective
to serotonergic neuronal cells. Notably, MAO-A also
catalyzes the degradation of dopamine and norepineph-
rine, as well as serotonin, implying a broader array of
functions beyond serotonin catabolism in the cortex,
perhaps explaining the differences between cell culture
results and those obtained in rodent models.
MAO-A is a gene of interest that has been given the
moniker “warrior gene” as it has been linked to aggres-
sion in observational and survey-based studies [21]. In
addition, MAO-A knockout mice are more aggressive
than their wild-type littermates or mice null for MAO-B,
which degrades a different set of neurotransmitters [22].
The transcriptional regulation of MAO-A has not been
fully characterized but, in a recent computational and
experimental analysis of Mao-A expression, Gupta et al.
[23] identified critical roles for a conserved proximal
promoter domain (− 71/− 40 bp) in cis, and transcription
factors Sp1/Gata2/Tbp in trans, to govern mouse Mao-A
gene basal expression in a coordinated manner. We have
located, in silico, a near-consensus candidate VDRE,
consisting of a direct repeat with a spacer of three nucle-
otides (DR3), CGGACActgAGGTCA (antisense), at +
776 in relation to the start of transcription of the human
MAO-A gene. Furthermore, Tuoresmaki et al. [16] have
reported two VDR ChIP-seq target regions (roughly
200 bp in size) in the human MAO-A gene, the first of
which overlaps the candidate DR3 VDRE at + 776 bp
cited above and the second, located approximately350 bp 3-prime to the first, which contains two add-
itional candidate (antisense)VDREs: GGTGCAggaGGTT
CT and GGTGCAggaGGTGCT. It is not yet known
whether these putative VDREs are involved in MAO-A
control by 1,25D, but their proximity to the core regula-
tory module at − 71/− 40 bp is suggestive of a possible
cis regulatory module spanning the proximal promoter
and first exon of the MAO-A gene. If this concept is
verified, yet another avenue may exist whereby 1,25D
could not only benefit patients with behavioral patho-
physiologies resulting from dysregulation of serotonergic
neurotransmission, but also impact other behavioral
traits and neurological disorders, including Alzheimer’s
dementia, aggression, and attention deficit hyperactivity
disorder [23].
The present results support the vitamin D-serotonin
hypothesis both experimentally and mechanistically. In
fact, when we assessed the direct production of sero-
tonin in neuronal cell culture in response to treatment
with 10 nM 1,25D for 72 h, serotonin concentrations
were significantly enhanced (two- to threefold) in the
medium (Fig. 5), consistent with the concerted induction
of TPH2 (Fig. 4b) and repression of SERT (Fig. 1a) and
MAO-A (Fig. 1b) by the empirically optimum level of
1,25D in cultured serotonergic neurons. Taking all of
these results together, it seems highly likely that vitamin
D can amplify serotonin in the central nervous system,
making vitamin D a candidate for the treatment of
neuropsychiatric disorders in which vitamin D and/or
serotonin are implicated. Indeed, vitamin D supplemen-
tation has been reported to improve inattention, hyper-
activity, and impulsivity in children and adults with
ADHD [24].
Conclusions
The results reported herein, combined with our previous
work and that of Patrick and Ames [1, 6], lead us to con-
clude that a set of tryptophan metabolism pathway en-
zymes/proteins relevant to CNS levels of serotonin are
transcriptionally regulated by 1,25D in differentiated se-
rotonergic rat raphe RN46A-B14 cells in such a fashion
as to suggest that optimum levels of the vitamin D hor-
mone represent a natural effector in spurring serotonin.
Strikingly, the modulation of the tryptophan metabolism
pathway by 1,25D at the transcriptional level is con-
served to the degree that it is even prominent in a verte-
brate only distantly related to mammals, namely
developing zebrafish [25]. By potentially fine-tuning
serotonin concentrations in the synaptic cleft, as
depicted schematically in the model in Fig. 6, 1,25D may
be able to steer neurological control of such processes as
social behavior to prevent autism spectrum disorders
and depression. In summary, as illustrated in hypothet-
ical form in Fig. 6, we conclude that the vitamin D
Fig. 6 Actions of 1,25D/VDR on serotonin dynamics in the CNS at the serotonin synapse. This model depicts the fine-tuning of serotonin levels
by 1,25D via transcriptional regulation of TPH2, SERT, and MAO-A; the result of which is the potentiation of serotonergic nerve transmission.
Initially, (left) 1,25D induces TPH2 to enhance serotonin output and, because circled pathway 3 (reuptake and degradation) is attenuated by 1,25D
via repression of SERT and MAO-A, serotonin action is spurred at both presynaptic (circled pathway 2) and postsynaptic (circled pathway 1) sites
through type 1A and 2A serotonin receptors, respectively
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centrations in relevant regions of the brain where both
VDR and TPH2, as well as SERT and MAO-A, are
expressed, placing this nutrient at the forefront of nutri-
genomic efforts to guide gene expression in serotonergic
neurons toward ameliorating neuropsychiatric disease by
spurring the actions of serotonin.Methods
Mammalian cell culture
Two mammalian cell lines were employed in this study:
embryonic rat medullary raphe (RN46A-B14; obtained
from Dr. Robert J. Handa/Dr. John Neumaier) cultured
with neurobasal A (Gibco/Life Technologies, Grand
Island, NY) medium with B-27 supplement (Invitrogen
Corporation) and L-glutamine (Gibco) and human brain
glioblastoma/astrocytoma (U-87 MG, U87; obtained from
the American Type Culture Collection) grown in DMEM/
high glucose + L-glutamine + pyruvate (Hyclone, Logan,
Utah). All cells were passaged in the above-indicated
media supplemented with 10% FBS and penicillin/strepto-
mycin (pen-strep) under a humidified atmosphere of 5%
CO2 in air at 37 °C. RN46A-B14 cells in culture were uti-
lized in their native state, i.e., not transfected with any
expression vector. However, U87 cells were transfected
with a VDR overexpression plasmid to ensure that they
consistently expressed biologically functional levels of the
nuclear receptor. The PolyJET transfection reagent (Signa-
Gen, Rockville, MD) was utilized to transfect U87 cells
according to the manufacturer’s protocol. Briefly, each
well was transfected with 15 μL PolyJET reagent and
500 ng of pSG5-hVDR (plasmid-expressing human VDR).The clonal cell line, RN46A-B14, was isolated following
transfection of the gene encoding rat brain-derived neuro-
trophic factor (BDNF) into RN46A cells [26]. RN46A-B14
cells synthesize and secrete biologically active BDNF
in vitro and synthesize serotonin following partial mem-
brane depolarization. To optimize the growth conditions
and neuronal morphology of adherent, rat serotonergic
B14 cells in culture, three different media formulations
were examined: media 1: neurobasal A medium, B-27 sup-
plement, L-glutamine, and pen-strep (serum free); media
2: media 1 plus 10% FBS; media 3: DMEM/high glucose +
L-glutamine + pyruvate, 10% FBS, and pen-strep.
Quantitative real-time PCR
U87 and RN46A-B14 cells were plated at 500,000–
800,000 cells per well in a 6-well plate, and dosed with
1–100 nM 1,25D (see Figs. 1, 2, 3 and 4) or ethanol ve-
hicle control for 24 h. Total RNA was isolated from each
well using an Aurum Total RNA Mini kit (Bio-Rad,
Hercules, CA) according to the manufacturer’s instruc-
tions. The RNA quantity and quality were assessed using
A260/280 spectrophotometry. DNase-treated RNA (1 μg)
was reverse transcribed using an iScript cDNA Synthesis
kit (Bio-Rad) to produce 20 μL of first-strand cDNA. For
real-time PCR, 2 μL of cDNA was used in a 10 μL PCR
reaction containing 5 μL FastStart Universal SYBR
Green Master Mix + Rox (Roche Applied Science, In-
dianapolis, IN) and forward and reverse primers. Reac-
tions were performed in 96-well PCR plates in a Bio-Rad
CFX96 instrument using a standard 40-cycle profile.
Data were analyzed using the comparative ΔΔCt method
as means of relative quantitation, normalized to an en-
dogenous reference (GAPDH) and relative to a calibrator
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expressed as 2-ΔΔCt according to Applied Biosystems’
User Bulletin 2: Rev. B, “Relative Quantitation of Gene
Expression.” Primer sets for the PCR were as follows:
Rat GAPDH (forward 5′-AGGTCGGTGTGAACGGATT
TG-3′, reverse 5′-CATTCTCAGCCTTGACTGTGC-3′)
Rat Cyp24a1 (forward 5’-AACGAAGCCTACGGGTT
GATG-3′, reverse 5’-AGAAAGTCAGCCAAGACCTCA-3′)
Rat SERT [27] (forward 5′-TCTGAAAAGCCCCACT
GGACT-3′, reverse 5′-TAGGACCGTGTCTTCATCAG
GC-3′)
Rat MAOA [28] (forward 5′-CCACAGCCAGAGCGT
TCAG-3′, reverse 5′-TGAGAGCCTTTGCCCAGATT
G-3′)
Rat MAOB [28] (forward 5′-CAGTGGAAGCAGAGG
AGAG-3′, reverse 5′-TGCTGCCATACCTGAGATG-3′)
Rat TPH1 [29] (forward 5′-GCTGAACAAACTCT
ACCCAAC-3′, reverse 5′-TTCCCGATAGCCACAGTA
TT-3′)
Rat TPH2 [30] (forward 5′-CTCCAAGCTTCGCA
TCACAG-3′, reverse 5′-AGCACTTCAGGAAGCGTAC
C-3′)
Human GAPDH (forward 5′-ACAACTTTGGTATC
GTGGAAGGAC-3′, reverse 5′-CAGGGATGATGTTC
TGGAGAGC-3′)
Human CYP24A1 (forward 5′-CAGCGAACTGAACA
AATGGTCG-3′, reverse 5′-TCTCTTCTCATACAACA
CGAGGCAG-3′)
Human SERT [31] (forward 5′-TTCTCCCCTCCAAG
TGAATG-3′, reverse 5′-GGGGAATCCATGGAAATAA
G-3′)
Human MAOA [32] (forward 5′-TAAATGGTCTC
GGGAAGGTG-3′, reverse 5′-CCCAGGGCAGTTAC
TGATGT-3′)




To measure serotonin (5-HT) concentrations, colorimet-
ric competitive 5-HT enzyme-linked immunosorbent
assay (ELISA) experiments were performed utilizing the
Serotonin Research ELISA kit (Rocky Mountain Diag-
nostics, Inc., Colorado Springs, CO). RN46A-B14 were
plated at 700,000 cells per well in a six-well plate in
media 2 (see above for details) and incubated in a hu-
midified atmosphere of 5% CO2 at 37 °C overnight. The
following day, media 2 was aspirated and the cells were
gently washed with PBS to remove residual serum.
Media 1 (see above for details) was added, and the cells
were incubated overnight to generate a serum-deprived
cell state. Next, the cells were treated with either ethanol
vehicle control or 10 nM 1,25D for 0–72 h in media 1.
Samples of media/culture supernatant (200 μL) wereremoved from each well (without disrupting the adher-
ent cells) at 0, 24, 48, or 72 h and assayed for 5-HT con-
tent in accordance with the manufacturer’s protocol.
Briefly, the diluent, wash buffer, six standards, and two
positive controls were prepared at the time of the assay,
and 100 μL of the diluted standards, controls, and ex-
perimental samples were acylated for 30 min at room
temperature. Next, 100 μL of the acylated standards,
controls, and experimental samples were placed into the
appropriate wells of the serotonin/5-HIAA microtiter
strips, and 25 μL of the 5-HT antiserum were added to
each well and incubated for 15–20 h at 4 °C. The wells
were washed, and 100 μL of the enzyme conjugate were
added and allowed to incubate for 30 min followed by
additional washes and incubation with 100 μL of the
substrate. After the final incubation, 100 μL of the stop
solution were added and the absorbance was read within
10 min using a microplate reader set to 450 nm and a
reference wavelength between 620 and 650 nm. The cali-
bration curve was obtained by plotting the absorbance
readings measured for the standards (linear, y axis)
against the corresponding standard concentrations (lin-
ear, x axis, ng/mL). A logarithmic trendline was fitted to
the data for the standards and the corresponding equa-
tion was utilized to determine the serotonin concentra-
tions in the experimental samples. The mean of three
biological replicates, each with duplicate treatment
groups, was utilized in the analysis.
Statistical analysis
Data are expressed as means ± SD. All data are presented
as fold-effects, with transcription of the gene in question
(i.e., mRNA level) in the absence of 1,25D (i.e., ethanol ve-
hicle) set at 1.0-fold. Thus, all results are normalized to
basal transcription and presented graphically and numer-
ically as fold-effect of the single tested variable, i.e., 1,25D.
Because the design of the experiments was a simple motif
in which the fold-ability of 1,25D to enhance transcription
over basal (i.e., ethanol vehicle) was assessed, statistical
differences between two groups were determined initially
by a two-tailed Student’s t test. However, because variance
was high in several experiments, further statistical analyses
were performed using GraphPad Prism 7 to generate
ANOVA data, followed by a post hoc Dunnett test that
compares every mean to a control mean and takes into ac-
count the scatter of all the groups. In each figure illustrat-
ing the fold-effect of 1,25D, exact P values (unless
< 0.0001) are listed above the bar for concentrations of
1,25D versus EtOH control, except when the difference
from the vehicle control is not significant (NS); a P value
less than 0.05 is considered significant.
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